Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OXiGENE Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/08/07/oxigene-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/
$OXGN OXiGENE Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/08/07/oxigene-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/
$BDSI BioDelivery: Clonidine Gel Is Significantly Undervalued By Investors, Says Roth Capital http://www.smarteranalyst.com/2014/08/07/biodelivery-we-believe-that-clonidine-gel-is-significantly-undervalued-by-investors-says-roth-capital/
$ZNGA Analysts Set Expectations On Zynga Into Second Quarter Earnings http://www.smarteranalyst.com/2014/08/06/analysts-set-expectations-on-zynga-into-second-quarter-earnings/
$AOL Topeka Maintains Buy Rating On AOL Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/topeka-maintains-buy-rating-on-aol-following-2q14-results/
$AOL Topeka Maintains Buy Rating On AOL Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/topeka-maintains-buy-rating-on-aol-following-2q14-results/
Topeka Maintains Buy Rating On AOL Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/topeka-maintains-buy-rating-on-aol-following-2q14-results/
Teva Is Now Well Positioned To Rebuild The Company With Organic Growth, Says Maxim http://bit.ly/1pCFVwj
Roth Capital Reiterates Buy On Sunesis Pharmaceuticals Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/roth-capital-reiterates-buy-on-sunesis-pharmaceuticals-following-2q14-results/
Roth Capital Reiterates Buy On Regeneron Following 2Q14 Results; Keeps $399 Price Target http://www.smarteranalyst.com/2014/08/06/roth-capital-reiterates-buy-on-regeneron-following-2q14-results-keeps-399-price-target/
We View NSPH Shares As Undervalued At Current Levels, Says Roth Capital http://www.smarteranalyst.com/2014/08/06/we-view-nsph-shares-as-undervalued-at-current-levels-says-roth-capital/
Maxim Group Reaffirms Buy On Cesca Therapeutics Following Collaboration Agreement With Fortis http://www.smarteranalyst.com/2014/08/06/maxim-group-reaffirms-buy-on-cesca-therapeutics-following-collaboration-agreement-with-fortis/
$OMER Maxim Reaffirms Buy On Omeros Ahead Of 2Q14 Results, Sees 73% Upside http://www.smarteranalyst.com/2014/08/06/maxim-reaffirms-buy-on-omeros-ahead-of-2q14-results-sees-73-upside/
$DSCO Roth Capital Maintains Buy On Discovery Laboratories Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/roth-capital-maintains-buy-on-discovery-laboratories-following-2q14-results/
$DSCO Roth Capital Maintains Buy On Discovery Laboratories Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/roth-capital-maintains-buy-on-discovery-laboratories-following-2q14-results/
$DSCO Roth Capital Maintains Buy On Discovery Laboratories Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/roth-capital-maintains-buy-on-discovery-laboratories-following-2q14-results/
$ANIP Roth Capital Reiterates Buy On Ani Pharmaceuticals Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/roth-capital-reiterates-buy-on-ani-pharmaceuticals-following-2q14-results/
$ANIP Roth Capital Reiterates Buy On Ani Pharmaceuticals Following 2Q14 Results http://www.smarteranalyst.com/2014/08/06/roth-capital-reiterates-buy-on-ani-pharmaceuticals-following-2q14-results/
H.C. Wainwright Reiterates Buy On Cesca Therapeutics Following Collaboration Agreement Extension http://www.smarteranalyst.com/2014/08/06/h-c-wainwright-reiterates-buy-on-cesca-therapeutics-following-collaboration-agreement-extension/
$JMBA Roth Capital Retains Neutral On Jamba Following 2Q14 Results; Raises PT To $13 http://www.smarteranalyst.com/2014/08/06/roth-capital-retains-neutral-on-jamba-following-2q14-results-raises-pt-to-13/
$ETRM Roth Capital Reaffirms Buy On EnteroMedics Ahead Of 2Q14 Results; Keeps $5 PT http://www.smarteranalyst.com/2014/08/06/roth-capital-reaffirms-buy-on-enteromedics-ahead-of-2q14-results/
Roth Capital Reiterates Buy On Craft Brew Ahead Of Second Quarter Earnings http://www.smarteranalyst.com/2014/08/06/roth-capital-reiterates-buy-on-craft-brew-ahead-of-second-quarter-earnings/
Roth Capital Reaffirms Buy On Acura Pharmaceuticals Following 2Q14 Results; Sees Partnership Opportunity http://www.smarteranalyst.com/2014/08/06/roth-capital-reaffirms-buy-on-acura-pharmaceuticals-following-2q14-results-sees-partnership-opportunity/
$ACUR Roth Capital Reaffirms Buy On Acura Pharmaceuticals Following 2Q14 Results; Sees Partnership Opportunity http://www.smarteranalyst.com/2014/08/06/roth-capital-reaffirms-buy-on-acura-pharmaceuticals-following-2q14-results-sees-partnership-opportunity/
$LJPC La Jolla Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/08/05/la-jolla-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/
$ZNGA Wedbush Maintains Outperform On Zynga Ahead Of 2Q14 Report; Sees %146 Upside http://www.smarteranalyst.com/2014/08/05/wedbush-maintains-outperform-on-zynga-ahead-of-2q14-report-sees-6-upside/
ZNGA Wedbush Maintains Outperform On Zynga Ahead Of 2Q14 Report; Sees %146 Upside http://www.smarteranalyst.com/2014/08/05/wedbush-maintains-outperform-on-zynga-ahead-of-2q14-report-sees-6-upside/
ZNGA Wedbush Maintains Outperform On Zynga Ahead Of 2Q14 Report; Sees %146 Upside http://www.smarteranalyst.com/2014/08/05/wedbush-maintains-outperform-on-zynga-ahead-of-2q14-report-sees-6-upside/
$ZNGA Wedbush Maintains Outperform On Zynga Ahead Of 2Q14 Report; Sees %146 Upside http://www.smarteranalyst.com/2014/08/05/wedbush-maintains-outperform-on-zynga-ahead-of-2q14-report-sees-6-upside/
$ZNGA Wedbush Maintains Outperform On Zynga Ahead Of 2Q14 Report; Sees %146 Upside http://www.smarteranalyst.com/2014/08/05/wedbush-maintains-outperform-on-zynga-ahead-of-2q14-report-sees-6-upside/
Wedbush Maintains Outperform On Zynga Ahead Of 2Q14 Report; Sees %146 Upside http://www.smarteranalyst.com/2014/08/05/wedbush-maintains-outperform-on-zynga-ahead-of-2q14-report-sees-6-upside/
$CTIC H.C. Wainwright Reiterates Buy On CTI Biopharma Following 2Q14 Earnings Report http://www.smarteranalyst.com/2014/08/05/h-c-wainwright-reiterates-buy-on-cti-biopharma-following-2q14-earnings-report/
Roth Capital Maintains Buy On Ur-Energy Following 2Q14 Earnings; Keeps $1.50 PT http://www.smarteranalyst.com/2014/08/05/roth-capital-maintains-buy-on-ur-energy-following-2q14-earnings-keeps-1-5-pt/
Roth Capital Maintains Bullish Stance On Ligand Following 2Q14 Results http://www.smarteranalyst.com/2014/08/05/roth-capital-maintains-bullish-stance-on-ligand-following-2q14-results/
$WETF WisdomTree: We Remain On The Sidelines, Says William Blair http://www.smarteranalyst.com/2014/08/05/wisdomtree-we-remain-on-the-sidelines-says-william-blair/
$AEZS H.C. Wainwright Reiterates Buy On Aeterna Zentaris; Sees %154 Upside http://www.smarteranalyst.com/2014/08/05/h-c-wainwright-reiterates-buy-on-aeterna-zentaris-sees-4-upside/
$AEZS H.C. Wainwright Reiterates Buy On Aeterna Zentaris; Sees %154 Upside http://www.smarteranalyst.com/2014/08/05/h-c-wainwright-reiterates-buy-on-aeterna-zentaris-sees-4-upside/
H.C Wainwright Reaffirms Buy On Insmed Following New Managment Plan For Arikayce http://www.smarteranalyst.com/2014/08/05/h-c-wainwright-reaffirms-buy-on-insmed-following-new-managment-plan-for-arikayce/
$INSM H.C Wainwright Reaffirms Buy On Insmed Following New Managment Plan For Arikayce http://www.smarteranalyst.com/2014/08/05/h-c-wainwright-reaffirms-buy-on-insmed-following-new-managment-plan-for-arikayce/
$ZGNX William Blair Reaffirms Outperform On Zogenix, But Reduces PT To $3 Given Reduced Zohydro Expectations
http://www.smarteranalyst.com/2014/08/05/william-blair-reaffirms-outperfom-on-zogenix-but-reduces-pt-to-3-given-reduced-zohydro-expectations/